At present, the US Food and Drug Administration has granted a fast track for paxalisib, a PI3K inhibitor, to treat newly diagnosed glioblastoma patients with unmethylated MGMT gene promoter, who have completed preliminary radiotherapy and temozolomide treatment. Here, PIK3CG is linked to glioblastoma.